Investment Thesis
BioMarin maintains a fortress balance sheet with excellent liquidity and strong free cash flow generation (26.1% FCF margin), providing financial stability. However, net income declined 18.3% YoY despite 12.9% revenue growth, and critically low ROE (1.7%) and ROA (1.2%) reveal severe capital efficiency problems, suggesting operational headwinds or significant non-cash charges offsetting growth.
Strengths
- Outstanding liquidity position (5.81x current ratio, 4.20x quick ratio) provides financial flexibility
- Strong free cash flow generation of $199.7M with 26.1% FCF margin conversion
- Healthy balance sheet with low leverage (0.23x debt-to-equity) and $2.2B cash reserves
- Solid revenue growth of 12.9% YoY in competitive pharmaceutical sector
- Strong interest coverage (13.5x) indicates minimal financial distress risk
Risks
- Net income declined 18.3% YoY while revenue grew 12.9%, indicating margin compression or rising operating expenses
- Extremely low return on equity (1.7%) and return on assets (1.2%) suggest poor capital deployment efficiency
- EPS declined 18.6% YoY, worse than net income decline, potentially indicating share dilution or concentrated losses
- Pharma sector typically requires sustained R&D investment; unclear if current spending is generating future value
Key Metrics to Watch
- Operating expense ratio trend - key to understanding margin compression
- Product pipeline productivity and clinical trial progress to assess future revenue quality
- Free cash flow sustainability relative to capital expenditure obligations
- Return on equity trajectory - must improve from current 1.7% level
Financial Metrics
Revenue
766.2M
Net Income
105.5M
EPS (Diluted)
$0.54
Free Cash Flow
199.7M
Total Assets
8.6B
Cash
2.2B
Profitability Ratios
Gross Margin
N/A
Operating Margin
16.9%
Net Margin
13.8%
ROE
1.7%
ROA
1.2%
FCF Margin
26.1%
Balance Sheet & Liquidity
Current Ratio
5.81x
Quick Ratio
4.20x
Debt/Equity
0.23x
Debt/Assets
27.7%
Interest Coverage
13.55x
Long-term Debt
1.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:08:27.796106 |
Data as of: 2026-03-31 |
Powered by Claude AI